TOI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TOI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Oncology Institute's Total Assets for the quarter that ended in Dec. 2024 was $172.7 Mil.
Warning Sign:
If a company builds assets at 21.6% a year, faster than its revenue growth rate of 15.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, The Oncology Institute's average Total Assets Growth Rate was -2.60% per year. During the past 3 years, the average Total Assets Growth Rate was 11.30% per year. During the past 5 years, the average Total Assets Growth Rate was 21.60% per year.
During the past 7 years, The Oncology Institute's highest 3-Year average Total Assets Growth Rate was 48.80%. The lowest was 11.30%. And the median was 28.40%.
Total Assets is connected with ROA %. The Oncology Institute's annualized ROA % for the quarter that ended in Dec. 2024 was -29.97%. Total Assets is also linked to Revenue through Asset Turnover. The Oncology Institute's Asset Turnover for the quarter that ended in Dec. 2024 was 0.57.
The historical data trend for The Oncology Institute's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Total Assets | Get a 7-Day Free Trial | 65.69 | 203.44 | 261.67 | 209.24 | 172.72 |
The Oncology Institute Quarterly Data | ||||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
209.24 | 204.53 | 179.60 | 179.18 | 172.72 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
The Oncology Institute's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (A: Dec. 2024 ) | + | Total Liabilities (A: Dec. 2024 ) |
= | 3.589 | + | 169.128 | |
= | 172.7 |
The Oncology Institute's Total Assets for the quarter that ended in Dec. 2024 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2024 ) | + | Total Liabilities (Q: Dec. 2024 ) |
= | 3.589 | + | 169.128 | |
= | 172.7 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (NAS:TOI) Total Assets Explanation
Total Assets is connected with ROA %.
The Oncology Institute's annualized ROA % for the quarter that ended in Dec. 2024 is
ROA % | = | Net Income (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | -52.728 | / | ( (179.183 | + | 172.717) | / 2 ) | |
= | -52.728 | / | 175.95 | ||||
= | -29.97 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
The Oncology Institute's Asset Turnover for the quarter that ended in Dec. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2024 ) | / | ( (Total Assets (Q: Sep. 2024 ) | + | Total Assets (Q: Dec. 2024 )) | / count ) |
= | 100.267 | / | ( (179.183 | + | 172.717) | / 2 ) |
= | 100.267 | / | 175.95 | |||
= | 0.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of The Oncology Institute's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Brad Hively | director, officer: Chief Executive Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Havencrest Healthcare Partners, L.p. | 10 percent owner | 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039 |
Mihir Shah | officer: Chief Financial Officer, other: Principal Financial Officer | C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801 |
Jeremy Castle | officer: Chief Operating Officer | 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richard A Barasch | director, officer: Executive Chairman | C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573 |
Matthew P Miller | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Daniel Virnich | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Yale Podnos | officer: Chief Medical Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Diona Simoneit | officer: Chief Accounting Officer, other: Principal Accounting Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mohit Kaushal | director | 44 SOUTH BROADWAY, WHITE PLAINS NY 10601 |
Gabriel Ling | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mark L Pacala | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richy Agajanian | 10 percent owner | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Maeve O'meara | director | C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105 |
Toi Hc I, Llc | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201 |
From GuruFocus
By GuruFocus Research • 03-27-2024
By GuruFocus News • 11-14-2024
By Marketwired • 09-30-2024
By GuruFocus News • 11-14-2024
By Marketwired • 11-13-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 08-14-2024
By Marketwired • 12-18-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 05-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.